Here, we demonstrated that NR4A1, whose expression was downregulated in TamR cells and patients with recurrent breast cancer treated with tamoxifen, may be a new prognostic factor and therapeutic target for tamoxifen resistance. Here, NR4A1 is linked to breast carcinoma.